Qiagen to Gain Array-Based Breast Cancer Test through Ipsogen Buy | GenomeWeb

By Justin Petrone

Qiagen's planned acquisition of Ipsogen will provide the firm not only with a suite of CE-IVD marked PCR tests but an Affymetrix-manufactured microarray test that can be used to guide treatment for breast cancer patients.

Qiagen last week announced its intent to acquire molecular diagnostics firm Ipsogen for €70 million ($101 million). Qiagen is headquartered in Venlo, The Netherlands. Ipsogen is based in Marseille, France.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: role for RNA splicing in genetic variation, and more.

An advocacy group sues the US Food and Drug Administration over redactions of information about advisory committee members, Stat News reports.

Mexico is trying to lure young genomics researchers back home with their own labs, Science reports.

A molecular autopsy has aided a woman's search for why sudden cardiac death has stalked her family, the Wall Street Journal reports.